跳至主要内容
临床试验/NCT00565162
NCT00565162已完成4 期

A Multicentre, Multinational, Randomised, Open Study to Establish the Optimal Method for Initiating Lantus(Insulin Glargine) Therapy to Determine Metabolic and Economic Outcomes, Safety, and Satisfaction in Subjects With Type 2 Diabetes Mellitus

Sanofi4 个研究点 分布在 4 个国家目标入组 124 人开始时间: 2003年11月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Sanofi
入组人数
124
试验地点
4
主要终点
Superiority is based on observing clinically significant difference in glycaemic control (> than or = to 0,5 % HbA1c). Programs are defined as equally successful if the HbA1c differs less than 0,5 %.

研究概览

简要总结

To introduce initiation of glargine insulin treatment in primary care based on a patient education program. To show and compare feasibility of group education to individual education program.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Insulin-naive Type 2 Diabetes Mellitus subjects, aged ≥18 years and on stable oral anti-diabetic treatment for >6 months requiring basal long-acting insulin (HbA1c >7.5 % and <12.0 %).

排除标准

  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

结局指标

主要结局

Superiority is based on observing clinically significant difference in glycaemic control (> than or = to 0,5 % HbA1c). Programs are defined as equally successful if the HbA1c differs less than 0,5 %.

时间窗: HbA1c values at visits 1, 2, 5 and 10

次要结局

未报告次要终点

研究者

发起方
Sanofi
申办方类型
Industry

研究点 (4)

Loading locations...

相似试验

Insulin Glargine, INITIATE Metabolic and Economic... | 临床试验